Also known as bremelanotide
A sexual health research peptide. Live vendor vial prices, sorted lowest first.
For research use only. Not for human consumption. No health, dosing, or usage claims are made.
PT-141 (bremelanotide) is a synthetic cyclic melanocortin-receptor agonist. As the drug bremelanotide it is FDA-approved as the finished product Vyleesi; peptide sold as a research chemical is not the approved finished drug product.
PT-141 is bremelanotide, the des-amino acid (free-acid, non-amidated) analog of melanotan II; on-file CAS 189691-06-3 matches PubChem for the free base.
Regulatory status: Bremelanotide (Vyleesi) was FDA-approved on June 21, 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD); other uses remain investigational.
Typical vendor vial prices, Jul 2026. Exact prices load with verified listings.
| Vendor | Vial price | |
|---|---|---|
Simple Peptide | $0.05Best | View vendor › |
Precision Research Peptides | $0.13 | View vendor › |
Prime Lab Peptides | $0.16 | View vendor › |
Koi Peptides | $0.18 | View vendor › |
Protide Health | $0.20 | View vendor › |
BioInfinity Lab | $0.22 | View vendor › |
Kaia Peptides | $0.33 | View vendor › |
BioLongevity Labs | $0.50 | View vendor › |
Mile High Compounds | $1 | View vendor › |
PSPeptides | $3.60 | View vendor › |
Skye Peptides | $8.80 | View vendor › |
Studied in clinical and laboratory research of melanocortin signaling; outside the approved HSDD indication these remain areas of study.
Planning a reconstitution? Use the calculator — it is math for handling a vial, not dosing.
Sources & further reading: PubChem CID 9941379 (NCBI) · FDA — Vyleesi (bremelanotide) prescribing information / label
How we source this ›